Study shows Sputnik V vaccine does not cause thrombosis – telam

An analysis of adverse events in clinical trials and in mass immunizations with the Sputnik V coronavirus vaccine has shown that “There have been no cases of cerebral venous sinus thrombosis,” the Gamaleya Center explained.

“All vaccines based on the adenoviral vector platform are different and not directly comparable. In particular, AstraZeneca’s ChAdOx1-S vaccine uses a chimpanzee adenovirus to deliver the antigen, which consists of the S protein combined with the leader sequence of the tissue-type plasminogen activator, “they explained from the Russian laboratory via a tweet made through your social network account.

They also added that “the Johnson & Johnson vaccine uses the human adenovirus serotype Ad26 and the full-length S protein stabilized by mutations. In addition, it is produced from the PER.C6 cell line (embryonic retinal cells), which is not widely represented among the other products registered ”.

“We are ready to share the purification technology with other vaccine producers to help them minimize the risk of side effects.”“

Centro gamaleya

The “Sputnik V” vaccine is a two-component vaccine using adenovirus serotypes 5 and 26. A tissue-like plasminogen activator fragment is not used and the antigenic insert is an unmodified full length S protein.Sputnik V is produced with the HEK293 cell line, which has long been used safely for the production of biotechnology products.“.

They went on to explain that “there is no reason to extrapolate the safety data of one vaccine to the safety data of others.”

And they recalled that “the quality and safety of Sputnik V are, among other things, ensured by the fact that, unlike other vaccines, it uses a 4-step purification technology which includes two chromatography steps and two filtration steps. in tangential flow ”. This technology “makes it possible to obtain a highly purified product which passes through a compulsory control which includes the analysis of the presence of free DNA”.

A study published in The New England Journal of Medicine on April 9, 2021, analyzes that the cause of thrombosis in some patients vaccinated with other vaccines “could be insufficient purification leading to the appearance of large amounts of free DNA” .

And they added that “insufficient purification or the use of very high doses of target DNA / RNA can lead to an unwanted interaction of a patient’s antibodies that activate platelets with elements of the vaccine itself and / or of the vaccine itself. free DNA / RNA, that they can form a complex with the factor PF4 ”.

Finally, they clarified that “Centro Gamaleya is ready to share its purification technology with other vaccine producers to help them minimize the risk of side effects during vaccination ”.